

Questions & Answers on licence application DIR 179 – Clinical trial with a genetically modified *Vaccinia virus* based treatment for solid cancerous tumours

What is this application for?

Novotech (Australia) Pty Limited is seeking approval for a clinical trial of genetically modified (GM) *Vaccinia virus* to treat solid cancerous tumours. In most patients with metastatic cancers, chemotherapy does not eliminate tumours. Thus, there is a need for novel treatments.

The proposed treatment uses a GM *Vaccinia virus*, which has been designed to preferentially multiply in, and kill cancer cells. It is predicted to significantly increase survival rates of patients that have been unresponsive to other treatments. The GM *Vaccinia virus* would be manufactured overseas and imported into Australia. It would be administered to up to 150 patients with advanced solid cancerous tumours at clinical trial sites and hospitals in Australia.

What other regulatory processes apply to this trial?

Clinical trials must be conducted in accordance with requirements of the Therapeutic Goods Administration (TGA), which address the safety of trial participants. Before commencing, the trials would require ethics approval, and must be conducted in accordance with the *Guidelines for Good Clinical Practice*. Import of the GM human adenovirus treatment will also require approval from the Department of Agriculture, Water and the Environment.

How has the GM treatment been created?

The GM treatment is based on *Vaccinia virus*, which was used as a vaccine during the global smallpox eradication campaign. The GM treatment has been modified by deletion of several genes so that it multiplies in and then kills cancerous tumour cells without affecting healthy cells. Three genes have also been introduced into the GM treatment that stimulate the body's immune system to recognise and kill tumour cells.

Has the GM treatment been previously tested or used?

The GM treatment is currently in a Phase1/2a clinical trial in the United States.

What controls are proposed for this release?

The consultation Risk Assessment and Risk Management Plan (RARMP) prepared for this application concluded that the clinical trial poses negligible risks to people or the environment. However, as this is a clinical trial under limited and controlled conditions, a number of licence conditions have been drafted to restrict when and where the trial can take place, limit the size of the trial, and restrict the spread and persistence of the GM treatment. For example, there are conditions relating to preparation and administration of the treatment, secure transport and storage of the treatment and appropriate waste disposal. Full details of the draft licence conditions are available in the consultation RARMP.

How can I comment on this application?

The full consultation RARMP and a summary of the RARMP for application DIR 179 are available on the [What's New](#) page of the [OGTR website](#) or via the contacts listed below. You are invited to submit your written comments on the consultation version of the RARMP, related to any risks to the health and safety of people or to the environment from the proposed clinical trial. Please note that issues such as **patient safety, quality and efficacy of a therapeutic products, and marketability and trade implications** do **NOT** fall within the scope of the evaluations conducted under the *Gene Technology Act 2000* as these are the responsibility of other agencies and authorities. Comments must be received by the close of the consultation period on 24 February 2021.

What are the next steps in the evaluation process?

The RARMP will be finalised, taking into account submissions related to the protection of people or the environment. A de-identified summary of all comments received and consideration of those comments is included in the Appendices to the final RARMP. The finalised RARMP will inform the Regulator's decision on whether or not to issue a licence.

The Office of the Gene Technology Regulator

[ogtr website](#)

Tel: 1800 181 030 E-mail: ogtr@health.gov.au